These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27272731)

  • 21. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of phosphorus load in CKD patients.
    Taketani Y; Koiwa F; Yokoyama K
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal bone disease.
    Sprague SM
    Curr Opin Endocrinol Diabetes Obes; 2010 Dec; 17(6):535-9. PubMed ID: 21030840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients.
    Kwon YE; Lee MJ; Park KS; Han SH; Yoo TH; Oh KH; Lee J; Lee KB; Chung W; Kim YH; Ahn C; Choi KH
    Yonsei Med J; 2017 Mar; 58(2):380-387. PubMed ID: 28120569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term management of CKD-mineral and bone disorder.
    Martin KJ; González EA
    Am J Kidney Dis; 2012 Aug; 60(2):308-15. PubMed ID: 22520454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD.
    Burton JO; Goldsmith DJ; Ruddock N; Shroff R; Wan M
    BMC Nephrol; 2018 Sep; 19(1):240. PubMed ID: 30236082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone Disorders in Chronic Kidney Disease: An Update in Diagnosis and Management.
    Babayev R; Nickolas TL
    Semin Dial; 2015; 28(6):645-53. PubMed ID: 26332760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
    Ennis JL; Worcester EM; Coe FL; Sprague SM
    J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of mineral bone disorder with pharmaceuticals which influence the calcium phosphor turnover].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2012 Nov; 174(47):2931-4. PubMed ID: 23171790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mineral and bone disorders in chronic heart failure].
    Reznik EV; Nikitin IG
    Kardiologiia; 2018 SFeb; (S2):42-62. PubMed ID: 29782253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research on kidney and mineral metabolism in Japan: past, present, and future.
    Mizobuchi M; Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):4-8. PubMed ID: 28005175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lowering Expectations with Niacin Treatment for CKD-MBD.
    Drüeke TB; Massy ZA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):6-8. PubMed ID: 29208625
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.
    Jiang JQ; Lin S; Xu PC; Zheng ZF; Jia JY
    Nephrology (Carlton); 2011 Aug; 16(6):588-94. PubMed ID: 21649792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.